Literature DB >> 25628072

Factors influencing quality decision-making: regulatory and pharmaceutical industry perspectives.

Ronan Donelan1, Stuart Walker, Sam Salek.   

Abstract

PURPOSE: Currently, there is no qualified understanding of the influences, behaviours and other factors that impact the decision-making of individuals and organisations involved in the development of new medicines. The aim of this qualitative study was to investigate and identify the important issues that influence quality decision-making.
METHODS: Semi-structured interviews were carried out with 29 senior decision-makers from the pharmaceutical industry and regulatory authorities. The study participants were invited to discuss and review their perception of decision-making within their organisation, its role in drug development and the regulatory review and their awareness and use of decision-making techniques and the impact and monitoring of decisions.
RESULTS: The analyses (using NVivo 8(©) software) resulted in the identification of 32 major and 97 sub-themes that were consolidated into 19 overarching themes. These included items such as quality and validity of data, time considerations, organisational and cultural influences, analytical and logical approach, qualification and experience, subjective and personal considerations, political influences, precedents for similar previous decisions, understanding of the decision in question, impact analyses, audit trail, education and awareness, individual versus corporate decision-making and frameworks. Relationships between themes were identified. The 19 overarching decision-making themes were integrated into a framework for quality decision-making.
CONCLUSION: This study has achieved its aim of exploring decision-making from the perspective of the individual and the organisation working in drug development and the regulatory review and has identified issues and considerations relating to making good quality decisions and allowed for the generation of a framework to aid quality decision-making.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  decision-making; framework; individual; interviews; organisation; pharmaceutical industry; pharmacoepidemiology; qualitative; quality; regulatory agencies

Mesh:

Year:  2015        PMID: 25628072     DOI: 10.1002/pds.3752

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  8 in total

1.  Impact of a five-dimensional framework on R&D productivity at AstraZeneca.

Authors:  Paul Morgan; Dean G Brown; Simon Lennard; Mark J Anderton; J Carl Barrett; Ulf Eriksson; Mark Fidock; Bengt Hamrén; Anthony Johnson; Ruth E March; James Matcham; Jerome Mettetal; David J Nicholls; Stefan Platz; Steve Rees; Michael A Snowden; Menelas N Pangalos
Journal:  Nat Rev Drug Discov       Date:  2018-01-19       Impact factor: 84.694

Review 2.  Evaluating Quality of Decision-Making Processes in Medicines' Development, Regulatory Review, and Health Technology Assessment: A Systematic Review of the Literature.

Authors:  Magdalena Bujar; Neil McAuslane; Stuart R Walker; Sam Salek
Journal:  Front Pharmacol       Date:  2017-04-10       Impact factor: 5.810

3.  The Reliability and Relevance of a Quality of Decision Making Instrument, Quality of Decision-Making Orientation Scheme (QoDoS), for Use During the Lifecycle of Medicines.

Authors:  Magdalena Bujar; Neil McAuslane; Stuart Walker; Sam Salek
Journal:  Front Pharmacol       Date:  2019-01-23       Impact factor: 5.810

4.  Quality Decision-Making Practices in Pharmaceutical Companies and Regulatory Authorities: Current and Proposed Approaches to Its Documentation.

Authors:  Magdalena Bujar; Neil McAuslane; Patricia Connelly; Stuart R Walker
Journal:  Ther Innov Regul Sci       Date:  2020-05-29       Impact factor: 1.778

Review 5.  Systematic literature review on the implicit factors influencing the HTA deliberative process in Europe.

Authors:  Clara Monleón; Hans-Martin Späth; Carlos Crespo; Claude Dussart; Mondher Toumi
Journal:  J Mark Access Health Policy       Date:  2022-06-28

6.  The Development and Validation of a Generic Instrument, QoDoS, for Assessing the Quality of Decision Making.

Authors:  Ronan Donelan; Stuart Walker; Sam Salek
Journal:  Front Pharmacol       Date:  2016-07-13       Impact factor: 5.810

7.  Decision frameworks for restoration & adaptation investment-Applying lessons from asset-intensive industries to the Great Barrier Reef.

Authors:  Mayuran Sivapalan; Jerome Bowen
Journal:  PLoS One       Date:  2020-11-03       Impact factor: 3.240

8.  A Process for Evaluating Quality Decision-Making Practices During the Development, Review and Reimbursement of Medicines.

Authors:  Magdalena Bujar; Neil McAuslane; Stuart Walker; Sam Salek
Journal:  Int J Health Policy Manag       Date:  2022-02-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.